Pharma Industry Manufacturing Is Ripe for a Digital Makeover

That’s because manufacturing failures, breakdowns or slow downs result in drug shortages. In fact, the Food and Drug Administration (FDA) reports that 65% of all drug shortages are caused by manufacturing and quality issues. And if drugs aren’t available to the people who need them, drastic doesn’t even begin to describe the effects on the patient.

So the FDA is working with pharma manufacturers to make significant improvements. One thing they are doing is reaching out to other industries, including electronics, chemicals and automotive, to find best practices that are transferrable to pharma and are helping drug manufacturers adopt the ideas and principles that are working elsewhere, the FDA Voice reports.

“The FDA is reaching out to other industries, including electronics, chemicals and automotive, to find best practices transferable to pharma.”

Among those best practices, according to McKinsey, are the use of advanced analytics, sensors, automation (Internet of Things) and 3D printing. One pharmaceutical company, in fact, has even tested using 3D technology to print Spritam—an epilepsy drug.

Aprecia, the manufacturer of Spritam, has exclusive rights to utilize Powder-liquid 3DP, a 3D printing technology developed by MIT in the 1980s. The technique enables the company’s ZipDose delivery platform. By printing a tablet consisting of layers of powder, Aprecia drugs can achieve a high degree of dissolvability in liquid. Aprecia recently received a $35 million round of funding to scale up its 3D process.

Novartis will likely introduce automation into its R&D and manufacturing facility as it works to reduce costs by another $1 billion over the next four years. Novartis is planning to centralize its manufacturing operations across divisions into a single technical operations unit, according to FiercePharmaManufacturing.

Meanwhile the pharma industry overall, unlike some other sectors, is at the very beginning stages of digital transformation, McKinsey says. To move forward, pharma manufacturers must think of themselves as solutions providers, not product makers.

The technology is ready, McKinsey says, but pharmaceuticals manufacturers still have a long way to go.


Lynn Russo Whylly

Share
Published by
Lynn Russo Whylly

Recent Posts

Growth 2026: Operator’s Playbook

A Workshop with Bob Nardelli

4 hours ago

From Supply Chain Chaos To Global Growth: How Women Executives Are Shaping Industrial Manufacturing

Innovation in manufacturing is not just about machines or technology; it’s about people.

3 days ago

CEO Health Checklist: The 8 Brain Must-Dos

It controls thought, movement and emotion. Here’s how to protect it and maximize its performance.

3 days ago

Pivoting To Partnerships: Why A Partner-Led Sales Model Can Fuel Your Growth

Changing sales strategy requires a new mindset, different skills and a thoughtful approach to execution.…

6 days ago

Why I Treat Talent Like A Dynamic Asset, Not A Fixed Resource

Freedom Trail Capital co-founder Samyr Laine on the qualities he looks for in founders—from adaptability…

6 days ago

Leadership Lessons From The Football Field: Build Teams, Not Followings

Both on the field and in the C-Suite, success hinges on work ethic and a…

7 days ago